Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Proleukin | Aldesleukin (IL-2) | In-transit Melanoma | Reimburse | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Stivarga (GIST) | Regorafenib | Gastrointestinal Stromal Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Stivarga Resubmission (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
Sylvant | Siltuximab | Multicentric Castleman's disease (MCD) | Reimburse with clinical criteria and/or conditions | Complete |